Drugs in Focus: Octreotide Use in Children With Gastrointestinal Disorders

Emmanuel Mas; Osvaldo Borrelli; Ilse Broekaert; J. Martin de-Carpi; Jernej Dolinsek; Erasmo Miele; Corina Pienar; C. Ribes Koninckx; Ruth-Anne Thomassen; Mike Thomson; Christo Tzivinikos; Marc A. Benninga

doi:10.1097/MPG.0000000000003294

Drugs in Focus: Octreotide Use in Children With Gastrointestinal Disorders

Emmanuel Mas^*
, Osvaldo Borrelli
, Ilse Broekaert
, J. Martin de-Carpi
, Jernej Dolinsek
, Erasmo Miele
, Corina Pienar
, C. Ribes Koninckx
, Ruth-Anne Thomassen
, Mike Thomson
, Christo Tzivinikos
, Marc A. Benninga^*

^*Corresponding author for this work

Hôpital des enfants
NIHR Great Ormond Street Biomedical Research Centre, London, UK
Center for Biochemistry, Faculty of Medicine, University of Cologne, Cologne, Germany
SJD Barcelona Children's Hospital
Department of Abdominal and General Surgery, Slovenia
University of Naples Federico II
Victor Babes University of Medicine and Pharmacy
Hospital Universitario La Fe
University of Oslo
Sheffield Children's NHS Foundation Trust
Department of Paediatric Gastroenterology, United Arab Emirates
University College London
Med. Fac. of the Univ. of Cologne
Hospital Sant Joan de Déu
Univerzitetni Klinični Center Maribor
Oslo University Hospital
Sheffield Children's Hospital
University of Amsterdam

Research output: Contribution to journal › Review article › Academic › peer-review

198 Downloads (Pure)

Abstract

Octreotide, a somatostatin analogue, has been used for more than 20 years in children with gastrointestinal bleeding, chylothorax or chylous ascites, intestinal lymphangiectasia, pancreatitis, intestinal dysmotility, and severe diarrhoea; however, until now, there is a lack of randomised clinical trials evaluating the efficacy of this compound in childhood. Hence, we aimed to review the literature in order to determine the evidence of its use and safety in children, using PubMed from 2000 to 2021 with the search terms ‘‘octreotide’’ and ‘‘children’’ and ‘‘bleeding or chylous ascites or chylothorax or acute pancreatitis or lymphangiectasia or diarrhoea or intestinal dysmotility’’.

Original language	English
Pages (from-to)	1-6
Number of pages	6
Journal	Journal of pediatric gastroenterology and nutrition
Volume	74
Issue number	1
DOIs	https://doi.org/10.1097/MPG.0000000000003294
Publication status	Published - 1 Jan 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Bleeding
Children
Chylous ascites
Diarrhoea
Ocreotide
Somatostatin

Access to Document

10.1097/MPG.0000000000003294

Drugs-in-focus.pdfFinal published version, 133 KB

Cite this

Mas, E., Borrelli, O., Broekaert, I., Martin de-Carpi, J., Dolinsek, J., Miele, E., Pienar, C., Ribes Koninckx, C., Thomassen, R.-A., Thomson, M., Tzivinikos, C., & Benninga, M. A. (2022). Drugs in Focus: Octreotide Use in Children With Gastrointestinal Disorders. Journal of pediatric gastroenterology and nutrition, 74(1), 1-6. https://doi.org/10.1097/MPG.0000000000003294

@article{2d9348a81ad04c7a8f1487862e13d88e,

title = "Drugs in Focus: Octreotide Use in Children With Gastrointestinal Disorders",

abstract = "Octreotide, a somatostatin analogue, has been used for more than 20 years in children with gastrointestinal bleeding, chylothorax or chylous ascites, intestinal lymphangiectasia, pancreatitis, intestinal dysmotility, and severe diarrhoea; however, until now, there is a lack of randomised clinical trials evaluating the efficacy of this compound in childhood. Hence, we aimed to review the literature in order to determine the evidence of its use and safety in children, using PubMed from 2000 to 2021 with the search terms {\textquoteleft}{\textquoteleft}octreotide{\textquoteright}{\textquoteright} and {\textquoteleft}{\textquoteleft}children{\textquoteright}{\textquoteright} and {\textquoteleft}{\textquoteleft}bleeding or chylous ascites or chylothorax or acute pancreatitis or lymphangiectasia or diarrhoea or intestinal dysmotility{\textquoteright}{\textquoteright}.",

keywords = "Bleeding, Children, Chylous ascites, Diarrhoea, Ocreotide, Somatostatin",

author = "Emmanuel Mas and Osvaldo Borrelli and Ilse Broekaert and \{Martin de-Carpi\}, J. and Jernej Dolinsek and Erasmo Miele and Corina Pienar and \{Ribes Koninckx\}, C. and Ruth-Anne Thomassen and Mike Thomson and Christo Tzivinikos and Benninga, \{Marc A.\}",

note = "Publisher Copyright: Copyright {\textcopyright} 2021 by European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition.",

year = "2022",

month = jan,

day = "1",

doi = "10.1097/MPG.0000000000003294",

language = "English",

volume = "74",

pages = "1--6",

journal = "Journal of pediatric gastroenterology and nutrition",

issn = "0277-2116",

publisher = "Lippincott Williams and Wilkins",

number = "1",

}

Mas, E, Borrelli, O, Broekaert, I, Martin de-Carpi, J, Dolinsek, J, Miele, E, Pienar, C, Ribes Koninckx, C, Thomassen, R-A, Thomson, M, Tzivinikos, C & Benninga, MA 2022, 'Drugs in Focus: Octreotide Use in Children With Gastrointestinal Disorders', Journal of pediatric gastroenterology and nutrition, vol. 74, no. 1, pp. 1-6. https://doi.org/10.1097/MPG.0000000000003294

TY - JOUR

T1 - Drugs in Focus

T2 - Octreotide Use in Children With Gastrointestinal Disorders

AU - Mas, Emmanuel

AU - Borrelli, Osvaldo

AU - Broekaert, Ilse

AU - Martin de-Carpi, J.

AU - Dolinsek, Jernej

AU - Miele, Erasmo

AU - Pienar, Corina

AU - Ribes Koninckx, C.

AU - Thomassen, Ruth-Anne

AU - Thomson, Mike

AU - Tzivinikos, Christo

AU - Benninga, Marc A.

N1 - Publisher Copyright: Copyright © 2021 by European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition.

PY - 2022/1/1

Y1 - 2022/1/1

N2 - Octreotide, a somatostatin analogue, has been used for more than 20 years in children with gastrointestinal bleeding, chylothorax or chylous ascites, intestinal lymphangiectasia, pancreatitis, intestinal dysmotility, and severe diarrhoea; however, until now, there is a lack of randomised clinical trials evaluating the efficacy of this compound in childhood. Hence, we aimed to review the literature in order to determine the evidence of its use and safety in children, using PubMed from 2000 to 2021 with the search terms ‘‘octreotide’’ and ‘‘children’’ and ‘‘bleeding or chylous ascites or chylothorax or acute pancreatitis or lymphangiectasia or diarrhoea or intestinal dysmotility’’.

AB - Octreotide, a somatostatin analogue, has been used for more than 20 years in children with gastrointestinal bleeding, chylothorax or chylous ascites, intestinal lymphangiectasia, pancreatitis, intestinal dysmotility, and severe diarrhoea; however, until now, there is a lack of randomised clinical trials evaluating the efficacy of this compound in childhood. Hence, we aimed to review the literature in order to determine the evidence of its use and safety in children, using PubMed from 2000 to 2021 with the search terms ‘‘octreotide’’ and ‘‘children’’ and ‘‘bleeding or chylous ascites or chylothorax or acute pancreatitis or lymphangiectasia or diarrhoea or intestinal dysmotility’’.

KW - Bleeding

KW - Children

KW - Chylous ascites

KW - Diarrhoea

KW - Ocreotide

KW - Somatostatin

UR - https://www.scopus.com/pages/publications/85122744609

U2 - 10.1097/MPG.0000000000003294

DO - 10.1097/MPG.0000000000003294

M3 - Review article

C2 - 34508049

SN - 0277-2116

VL - 74

SP - 1

EP - 6

JO - Journal of pediatric gastroenterology and nutrition

JF - Journal of pediatric gastroenterology and nutrition

IS - 1

ER -

Drugs in Focus: Octreotide Use in Children With Gastrointestinal Disorders

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this